Infant Formula Safety Modernization Act of 2026

Enhanced Safety Testing: Manufacturers will be required to conduct pathogen and microorganism testing on both the finished infant formula and the manufacturing facilities (Section 2(a)(1)(A)(i-ii)). This ensures a more rigorous check for harmful substances like clostridium botulinum (Section 2(a)(1)(B)(i)).

Increased Transparency and Oversight: Manufacturers must submit written notification of any positive test result within one business day, even if the product hasn't left their control (Section 2(a)(1)(B)(iii)). Furthermore, the Secretary must notify specific Congressional committees about these positive results and certain inspection classifications (Section 2(b)).

Consistent Standards: The Commissioner of Food and Drugs will establish and enforce clear, consistent inspection and compliance standards for all infant formula products, regardless of where they come from (Section 2(a)(1)(B)(v)).

Increased Regulatory Burden on Manufacturers: Companies will be required to adhere to new regulations regarding environmental testing frequency, specific zone testing (Zones 2 and 3), and strict record-keeping for any positive pathogen test results (Section 2(a)(1)(B)(ii) and (iv)).

Strict Reporting Deadlines: Manufacturers face a very tight window, requiring them to provide written notification of positive test results within one business day (Section 2(a)(1)(B)(iii)).